Puretech Health/£PRTC

1D1W1MYTD1Y5YMAX

About Puretech Health

PureTech Health, trading under the ticker PRTC, is a biotechnology company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. Operating within the healthcare sector, the company leverages its deep expertise in the understanding of disease physiology to advance a pipeline of novel therapies addressing serious medical conditions. Founded in 2015, PureTech Health engages in groundbreaking translational research that bridges the gap between innovative biological insights and potential impactful therapies.
Ticker
£PRTC
Sector
Health
Primary listing
LSE
Employees
90
Headquarters
Boston, United States
Website
www.puretechhealth.com

Puretech Health Metrics

BasicAdvanced
£297M
-
-£0.34
0.78
-

What the Analysts think about Puretech Health

Analyst ratings (Buy, Hold, Sell) for Puretech Health stock.
Analyst projections of the future price of Puretech Health stock.

Bulls say / Bears say

Seaport’s May IPO raised $260 million while PureTech retained a 31.2% stake, valued at about $360 million in September, plus royalty and milestone rights. That gives PureTech a potentially valuable, liquid asset without having to fund Seaport’s pipeline alone. (MarketBeat, Stockopedia)
Celea completed a $180 million financing and began the global Phase 3 SURPASS-IPF trial of deupirfenidone for idiopathic pulmonary fibrosis. PureTech retains a meaningful equity interest and future royalty, milestone and sublicensing rights while external investors fund much of the late-stage work. (Stockopedia, MarketBeat)
LYT-200 produced a 27.3% complete response rate and a 45.5% overall response rate in evaluable patients at the selected dose, and the FDA has agreed a path into Phase 2 while granting Fast Track status. This improves the chance that Gallop can attract outside funding and advance a potentially valuable oncology asset. (Investegate, MarketBeat)
Gallop still needs external financing before it can start the planned 125-patient STRIDE-MDS Phase 2 trial, with funding targeted for the first half of 2027. A delay or difficult financing could slow development or dilute PureTech’s economic interest. (MarketBeat, Investegate)
The encouraging LYT-200 response rates come from only 11 efficacy-evaluable patients at the 12 mg/kg dose, so they may not translate into a larger controlled trial. Separately, Seaport’s latest positive GlyphAllo result was a driving-simulation study in healthy volunteers, while its depression efficacy readout is not expected until the first half of 2027. (Investegate, Investegate)
PureTech’s first-half profit was driven mainly by a $120.4 million fair-value gain on investments, including a $121.0 million gain on Seaport, rather than recurring operating income. The business remains exposed to volatile asset valuations, milestone receipts and royalties, making headline earnings a poor guide to underlying performance. (MarketScreener, Investors' Chronicle)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.

Puretech Health Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Puretech Health Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.